Mantle Cell Lymphoma | Clinical

The Efficacy of Ibrutinib Plus Venetoclax for the Treatment of R/R MCL

February 18, 2021

Constantine Tam, MD, discuses the outcomes of the phase 3 Sympatico Study, which evaluated the safety and efficacy of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of relapsed or refractory mantle cell lymphoma compared to monotherapy.

KTE-X19 Continues to Show Durable Efficacy in Relapsed/Refractory MCL

February 12, 2021

After a minimum of 1 year of follow-up, patients with relapsed/refractory mantle cell lymphoma demonstrated substantial and durable clinical benefit and a manageable safety profile when receiving KTE-X19 chimeric antigen receptor T cell therapy.

New Chemotherapy-Free Option May Be Identified for Elderly Patients With MCL

February 05, 2021

In an interview with Targeted Oncology, Preetesh Jain, MBBS, MD, DM, PhD, assistant professor, reviewed the results seen with ibrutinib added to rituximab in older patients with mantle cell lymphoma and provided insight on how to manage the interesting toxicity profile observed with the combination.

Less Aggressive Treatment Warranted for MCL With Primary GI Involvement

January 27, 2021

Patients with mantle cell lymphoma and primary gastrointestinal involvement have similar outcomes to those with secondary gastrointestinal involvement, according to results from one of the largest known studies of gastrointestinal mantle cell lymphoma.

MCL35 Assay Stratifies Risk in Patients With Mantle Cell Lymphoma

December 21, 2020

A new multi-analyte prognostic assay has demonstrated the potential to risk-stratifying patients with mantle cell lymphoma based on the particular molecular signature of an individual patient’s cancer, according to a new study.

Parsaclisib Leads to Significant ORR in R/R MCL Without Prior BTK Exposure

December 21, 2020

Patients with relapsed or refractory mantle cell lymphoma treated with a daily dose of parsaclisib demonstrated significant activity and tolerability for the next-generation PI3Kδ inhibitor, according to findings from the phase 2 CITADEL-205 trial.